Hims & Hers Health, Inc. (HIMS) closed at $28.89 in the latest trading session, marking a -5.19% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 1.16% for the ...

Hims & Hers Health shows 50% revenue growth, $1B in cash, and 2.4x 2026 sales with strong personalization and GLP-1 sales.

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 2.2% in the morning session after Morgan ...

Hims & Hers Health (HIMS) is back in focus as investors reassess its telehealth model, weighing GLP-1 related interest and ...

Hims & Hers (NYSE: HIMS) is adding another specialty in an effort to build out its healthcare platform. The company has brought testosterone to the market, the first big addition since weight loss in ...

Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international expansion opportunities. Learn more about HIMS stock here.

Here's a look at the top 10 most heavily shorted stocks, including Lucid, MARA, Avis, Kohl's and Hims & Hers Health.

Financial giants have made a conspicuous bullish move on Hims & Hers Health. Our analysis of options history for Hims & Hers Health (NYSE:HIMS) revealed 13 unusual trades. Delving into the details, we ...

Hims & Hers and Tempus AI are transforming digital health in distinct ways, but which platform looks more compelling right ...

Virtual healthcare platforms are redefining patient access to care, with Hims & Hers Health, Inc. HIMS and GoodRx Holdings, Inc. GDRX among the leaders in this digital shift. HIMS is a consumer-first, ...